GENE-TRANSFER OF THE UROPORPHYRINOGEN-III SYNTHASE CDNA INTO HEMATOPOIETIC PROGENITOR CELLS IN VIEW OF A FUTURE GENE-THERAPY IN CONGENITAL ERYTHROPOIETIC PORPHYRIA
F. Mazurier et al., GENE-TRANSFER OF THE UROPORPHYRINOGEN-III SYNTHASE CDNA INTO HEMATOPOIETIC PROGENITOR CELLS IN VIEW OF A FUTURE GENE-THERAPY IN CONGENITAL ERYTHROPOIETIC PORPHYRIA, Journal of inherited metabolic disease, 20(2), 1997, pp. 247-257
Congenital erythropoietic porphyria (CEP) is an inherited metabolic di
sorder characterized by an overproduction and accumulation of porphyri
ns in bone marrow. This autosomal recessive disease results from a def
iciency of uroporphyrinogen III synthase (UROIIIS), the fourth enzyme
of the haem biosynthetic pathway. It is phenotypically heterogeneous:
patients with mild disease have cutaneous involvement, while more seve
rely affected patients are transfusion dependent. The cloning of UROII
IS cDNA and genomic DNA has allowed the molecular characterization of
the genetic defect in a number of families. To date, 22 different muta
tions have been characterized. Allogeneic bone marrow transplantation
is the only curative treatment available for the severe, transfusion-d
ependent, cases. When bone marrow transplantation cannot be performed
owing to the absence of a suitable donor, the autografting of genetica
lly modified cells is an appealing alternative. The best approach to s
omatic gene therapy in this disease involves the use of recombinant re
troviral vectors to transduce cells ex vivo, followed by autologous tr
ansplantation of the genetically modified cells. We investigated retro
viral transfer in deficient human fibroblasts, immortalized lymphoblas
ts as well as bone marrow cells, and obtained a complete restoration o
f the enzymatic activity and full metabolic correction. Using K562 cel
ls, an erythroleukaemic cell line, the expression of the transgene rem
ained stable during 3 months and during erythroid differentiation of t
he cells. Finally, a 1.6- to 1.9-fold increase in enzyme activity comp
ared to the endogenous level was found in normal CD34(+) cells, a popu
lation of heterogeneous cells known to contain the progenitor/stem cel
ls for long-term expression. The future availability of a mouse model
of the disease will permit ex vivo gene therapy experiments on the ent
ire animal.